🇺🇸 FDA
Patent

US 8022175

Production of anti-peptide monoclonal antibodies to distinguish Exotic New Castle diseases viruses from vaccine strains of Newcastle disease virus

granted A61PA61P37/00

Quick answer

US patent 8022175 (Production of anti-peptide monoclonal antibodies to distinguish Exotic New Castle diseases viruses from vaccine strains of Newcastle disease virus) held by The United States of America, as represented by the Secretary of Agriculture expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of Agriculture
Grant date
Tue Sep 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P37/00